• Je něco špatně v tomto záznamu ?

Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery

JC. Davies, P. Drevinek, JS. Elborn, E. Kerem, T. Lee, European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF', MD. Amaral, K. de Boeck, JC. Davies, P. Drevinek, JS. Elborn, E. Kerem, T. Lee,

. 2019 ; 18 (5) : 677-684. [pub] 20190711

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028831

The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group was brought together to consider these challenges and possible strategies to address them. Over the last 18 months, we have discussed internally and gathered views from a broad range of individuals representing patient organisations, clinical and research teams, the pharmaceutical industry and regulatory agencies. In this and the accompanying article, we discuss two main areas of focus: i) optimising trial design and delivery for speed and efficiency; ii) drug development for patients with rare CFTR mutations. We propose some strategies to tackle the challenges ahead and highlight areas where further thought is needed. We see this as the start of a process rather than the end and hope herewith to engage the wider community in seeking solutions to improved treatments for all patients with CF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028831
003      
CZ-PrNML
005      
20210114155214.0
007      
ta
008      
210105s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcf.2019.06.011 $2 doi
035    __
$a (PubMed)31303382
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Davies, Jane C $u National Heart & Lung Institute, Imperial College London, UK; Royal Brompton & Harefield NHS Foundation Trust, London, UK. Electronic address: j.c.davies@imperial.ac.uk.
245    10
$a Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery / $c JC. Davies, P. Drevinek, JS. Elborn, E. Kerem, T. Lee, European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF', MD. Amaral, K. de Boeck, JC. Davies, P. Drevinek, JS. Elborn, E. Kerem, T. Lee,
520    9_
$a The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group was brought together to consider these challenges and possible strategies to address them. Over the last 18 months, we have discussed internally and gathered views from a broad range of individuals representing patient organisations, clinical and research teams, the pharmaceutical industry and regulatory agencies. In this and the accompanying article, we discuss two main areas of focus: i) optimising trial design and delivery for speed and efficiency; ii) drug development for patients with rare CFTR mutations. We propose some strategies to tackle the challenges ahead and highlight areas where further thought is needed. We see this as the start of a process rather than the end and hope herewith to engage the wider community in seeking solutions to improved treatments for all patients with CF.
650    12
$a klinické zkoušky jako téma $x metody $x normy $7 D002986
650    _2
$a cystická fibróza $x farmakoterapie $x genetika $7 D003550
650    _2
$a protein CFTR $x genetika $7 D019005
650    12
$a vyvíjení léků $x organizace a řízení $x normy $7 D000076722
650    12
$a objevování léků $x metody $x trendy $7 D055808
650    _2
$a lidé $7 D006801
650    _2
$a modulátory membránového transportu $x farmakologie $7 D049990
650    _2
$a mutace $7 D009154
650    _2
$a zlepšení kvality $7 D058996
650    _2
$a výzkumný projekt $x normy $7 D012107
655    _2
$a časopisecké články $7 D016428
700    1_
$a Drevinek, Pavel $u Motol University Hospital Prague, Czech Republic.
700    1_
$a Elborn, J Stuart $u Queens University, Belfast, UK.
700    1_
$a Kerem, Eitan $u Hadassah Hebrew University Medical Center, Jerusalem, Israel.
700    1_
$a Lee, Tim $u Leeds Teaching Hospitals NHS Trust, Leeds, UK.
700    1_
$a Amaral, Margarida D $u University of Lisboa, Portugal.
700    1_
$a de Boeck, Kris $u University of Leuven, Belgium.
700    1_
$a Davies, Jane C $u National Heart & Lung Institute, Imperial College London, UK; Royal Brompton & Harefield NHS Foundation Trust, London, UK.
700    1_
$a Drevinek, Pavel $u Motol University Hospital Prague, Czech Republic.
700    1_
$a Elborn, J Stuart $u Queens University, Belfast, UK.
700    1_
$a Kerem, Eitan $u Hadassah Hebrew University Medical Center, Jerusalem, Israel.
700    1_
$a Lee, Tim $u Leeds Teaching Hospitals NHS Trust, Leeds, UK.
710    2_
$a European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF'
773    0_
$w MED00006892 $t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society $x 1873-5010 $g Roč. 18, č. 5 (2019), s. 677-684
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31303382 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155213 $b ABA008
999    __
$a ok $b bmc $g 1609166 $s 1120011
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 18 $c 5 $d 677-684 $e 20190711 $i 1873-5010 $m Journal of cystic fibrosis $n J Cyst Fibros $x MED00006892
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace